FEATURES
Samsung C&T Q3 2024 Earnings
[Overall Performance] Revenue: KRW 10.31T, Operating Profit: KRW 736B [Revenue] Decreased by KRW 661B (-6.0%) compared to KRW 10.971T in Q3 2023Decreased by KRW 695B (-6.3%) compared to KRW 11.005T in Q2 2024 [Operating Profit] Decreased by KRW 94B (-11.3%)
Samsung C&T Q2 2024 Earnings
[Overall Performance] Revenue: KRW 11.005T, Operating Profit: KRW 900B [Revenue] Increased by KRW 419B (4.0%) compared to KRW 10.586T in Q2 2023 Increased by KRW 209B (1.9%) compared to KRW 10.796T in Q1 2024 [Operating Profit] Increased by KRW 128B
Samsung invests in Flagship Pioneering Fund VIII
Samsung C&T Corporation, Samsung Biologics, Samsung Bioepis and Samsung Venture Investment Corporation (collectively hereinafter referred to as “Samsung”) announced today an investment into Flagship Pioneering Fund VIII (“Fund VIII”) to help fuel breakthrough innovations in human health and sustainability. In
ABOUT SAMSUNG C&T
IN NUMBERS
As of 2023